CO52 Modelling Long-Term Outcomes of Tirzepatide Compared to Lifestyle Modification and Other Anti-Obesity Medications As Treatment for Overweight and Obesity

SURMOUNT-1 demonstrated significant weight reduction and improvement in cardiometabolic risk factors with tirzepatide treatment, but data beyond 72 weeks are currently unavailable for people with overweight and obesity without T2DM. This study uses a patient-level simulation (PLS) to estimate long-term clinical outcomes with tirzepatide versus relevant comparators.